SLC7A5 and neoplasm: In an in vivo subcutaneous tumor model, knockdown of IGF2BP2 or SLC7A5 inhibited tumor growth and enhanced the antitumor effects of IR, while co-knockdown of IGF2BP2 and SLC7A5 had the strongest anti-tumor effects (Fig. 4G).